Nuveen Asset Management LLC Sells 8,634 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nuveen Asset Management LLC reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,530,519 shares of the biopharmaceutical company’s stock after selling 8,634 shares during the period. Nuveen Asset Management LLC’s holdings in Halozyme Therapeutics were worth $73,174,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Halozyme Therapeutics by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,087 shares of the biopharmaceutical company’s stock valued at $4,117,000 after buying an additional 3,874 shares during the period. Janus Henderson Group PLC lifted its stake in Halozyme Therapeutics by 28.8% during the fourth quarter. Janus Henderson Group PLC now owns 702,085 shares of the biopharmaceutical company’s stock worth $33,566,000 after purchasing an additional 156,912 shares during the last quarter. Gotham Asset Management LLC lifted its stake in Halozyme Therapeutics by 9.7% during the fourth quarter. Gotham Asset Management LLC now owns 47,440 shares of the biopharmaceutical company’s stock worth $2,268,000 after purchasing an additional 4,178 shares during the last quarter. Clark Capital Management Group Inc. lifted its stake in Halozyme Therapeutics by 30.4% during the fourth quarter. Clark Capital Management Group Inc. now owns 178,827 shares of the biopharmaceutical company’s stock worth $8,550,000 after purchasing an additional 41,655 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. The trade was a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,697 shares of company stock worth $1,276,552 over the last three months. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 6.3%

Shares of HALO opened at $52.02 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51. The stock has a market capitalization of $6.41 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a fifty day moving average of $60.69 and a 200-day moving average of $55.94.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Halozyme Therapeutics’s quarterly revenue was up 35.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.79 earnings per share. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 7th. Morgan Stanley cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $73.00 to $62.00 in a research note on Wednesday. Leerink Partnrs cut Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and a consensus price target of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.